Literature DB >> 2505541

MR findings in methotrexate-induced CNS abnormalities.

F Ebner1, G Ranner, I Slavc, C Urban, R Kleinert, H Radner, R Einspieler, E Justich.   

Abstract

MR of the brain was performed in eight patients (mean age, 14.9 years) with osteogenic sarcoma during or after IV treatment with high-dose methotrexate. MR detected brain abnormalities in four patients, three of whom had concomitant neurologic dysfunction. Pathologic findings demonstrated on MR were (1) chronic brain edema, demonstrable over a period of 3-14 months (proved by autopsy in one patient); (2) multifocal white matter necrosis; and (3) deep brain atrophy. MR appears to be valuable in the detection of abnormalities induced by treatment with high-dose methotrexate.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2505541      PMCID: PMC8335269     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  10 in total

1.  A case of treatment-related leukoencephalopathy: sequential MRI, CT and PET findings.

Authors:  S Miyatake; H Kikuchi; Y Oda; M Ishikawa; M Kojima; K Matsubayashi; J Minamikawa; S Yamagata; R Asato
Journal:  J Neurooncol       Date:  1992-10       Impact factor: 4.130

Review 2.  Atypical MRI findings in treatment-related leukoencephalopathy: case report.

Authors:  Y Ohmoto; K Kajiwara; S Kato; T Nisizaki; H Ito; S Tamura
Journal:  Neuroradiology       Date:  1996-02       Impact factor: 2.804

3.  Minor changes on cranial MRI during treatment in children with acute lymphoblastic leukaemia.

Authors:  E Pääkkö; L Vainionpää; J Pyhtinen; M Lanning
Journal:  Neuroradiology       Date:  1996-04       Impact factor: 2.804

4.  Transient encephalopathy after intrathekal methotrexate chemotherapy: diffusion-weighted MRI.

Authors:  W Küker; P Bader; U Herrlinger; S Heckl; T Nägele
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

5.  Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome.

Authors:  Nancy Rollins; Naomi Winick; Robert Bash; Timothy Booth
Journal:  AJNR Am J Neuroradiol       Date:  2004 Nov-Dec       Impact factor: 3.825

6.  Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery.

Authors:  Edward A Neuwelt; Paul E Guastadisegni; Péter Várallyay; Nancy D Doolittle
Journal:  AJNR Am J Neuroradiol       Date:  2005-02       Impact factor: 3.825

7.  Cyclosporin A toxicity: MRI appearance of the brain.

Authors:  M T Pace; T L Slovis; J K Kelly; S D Abella
Journal:  Pediatr Radiol       Date:  1995

8.  MRI in methotrexate-related leukoencephalopathy: Disseminated necrotising leukoencephalopathy in comparison with mild leukoencephalopathy.

Authors:  M Oka; S Terae; R Kobayashi; Y Sawamura; K Kudoh; K K Tha; M Yoshida; M Kaneda; Y Suzuki; K Miyasaka
Journal:  Neuroradiology       Date:  2003-05-22       Impact factor: 2.804

9.  Late cranial MRI after cranial irradiation in survivors of childhood cancer.

Authors:  E Pääkkö; K Talvensaari; J Pyhtinen; M Lanning
Journal:  Neuroradiology       Date:  1994-11       Impact factor: 2.804

10.  Methotrexate encephalopathy: Two cases in adult cancer patients, who recovered with pathophysiologically based therapy.

Authors:  Shodeinde A Coker; David A Pastel; Melissa C Davis; Elizabeth M Bengtson; Camilo E Fadul; Lionel D Lewis
Journal:  SAGE Open Med Case Rep       Date:  2017-05-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.